What is it about?
TTLL12 is a promising target for therapeutic intervention since it has been implicated in tumour progression and the innate immune response to viral infection. We identified a novel property of TTLL12, suppression of the cell toxicity of nitrotyrosine, which is produced by oxidative stress, modifies the cytoskeleton and is involved in cancer progression. We developed a robust assay based on this activity and used it to screen a collection of low-molecular weight molecules. Two molecules were identified that inhibit the pro-oncogenic activity of TTLL12.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
The molecules from the screen will be useful for the development of drugs to treat cancer and other pathologies that involve TTLL12.
Perspectives
We have been trying to find new ways to treat prostate and other cancers. We have managed to attract funding from many international sources and have worked in large multi-disciplinary consortiums. It has been a privilege to share this adventure not only with the talented and dedicated co-authors but also with many devoted scientists and clinicians.
Bohdan Wasylyk
IGBMC
Read the Original
This page is a summary of: TTLL12 has a potential oncogenic activity, suppression of ligation of nitrotyrosine to the C-terminus of detyrosinated α-tubulin, that can be overcome by molecules identified by screening a compound library, PLoS ONE, February 2024, PLOS,
DOI: 10.1371/journal.pone.0296960.
You can read the full text:
Contributors
The following have contributed to this page
